SAN DIEGO, CA, USA I January 6, 2014 I Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
Hani N. Sabbah, Ph.D., Professor of Medicine & Director of Cardiovascular Research at Henry Ford Health System, said: “These data clearly show that MST-188 improves left ventricular ejection fraction and end-systolic volume, both of which are important indicators of long-term mortality and morbidity in chronic heart failure, with some effects lasting up to 2 weeks post-infusion. The durability of response is very encouraging and merits clinical investigation.”
Santosh Vetticaden, M.D., Ph.D., Chief Medical Officer of Mast Therapeutics, said: “Heart failure is an area of significant unmet medical need that accounts for over 1 million hospitalizations every year in the U.S. alone. Although there have been modest improvements in treatment, heart failure remains associated with significant mortality and high rates of hospital admission and readmission. We look forward to discussing these results with heart failure experts and potential partners and mapping our clinical development strategy in this exciting new indication.”
The Company has submitted data from this study for presentation at an upcoming medical conference and will provide an update on its plans for MST-188 in heart failure later in 2014.
Details of the Study and Results
The objective of the study was to determine the effect of acute intravenous administration of MST-188 on left ventricular systolic and diastolic cardiac function in a model of chronic heart failure produced by multiple sequential intracoronary microembolizations. A single dose of MST-188 (low or high dose) or placebo was administered over 2 hours. Hemodynamic, ventriculographic, echocardiographic and electrocardiographic measurements were taken at baseline (prior to study drug administration) and at the following time-points after the start of study drug administration: 2 hours (end of administration), 24 hours, 1 week and 2 weeks. Peripheral venous blood samples were obtained at the same time-points. The improvements described above were calculated as the difference between baseline and mean values of each study group at each time-point using a one-way analysis of variance, with p
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).
The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease. In early 2014, the Company plans to initiate a phase 2, clinical proof of concept study in acute limb ischemia that will evaluate whether MST-188 improves the effectiveness of existing thrombolytic agents. The Company also is evaluating development options in heart failure. More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera)
SOURCE: Mast Therapeutics
Post Views: 232
SAN DIEGO, CA, USA I January 6, 2014 I Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in a placebo-controlled, nonclinical model of chronic heart failure, MST-188 demonstrated a statistically significant improvement in numerous parameters of heart function, including left ventricular ejection fraction and end-systolic volume, stroke volume and cardiac output. Notably, a single two-hour infusion of MST-188 resulted in improvements that were significant immediately (at the end of MST-188 administration) and remained significant at one week (and, in some cases, at two weeks) after MST-188 administration.
Hani N. Sabbah, Ph.D., Professor of Medicine & Director of Cardiovascular Research at Henry Ford Health System, said: “These data clearly show that MST-188 improves left ventricular ejection fraction and end-systolic volume, both of which are important indicators of long-term mortality and morbidity in chronic heart failure, with some effects lasting up to 2 weeks post-infusion. The durability of response is very encouraging and merits clinical investigation.”
Santosh Vetticaden, M.D., Ph.D., Chief Medical Officer of Mast Therapeutics, said: “Heart failure is an area of significant unmet medical need that accounts for over 1 million hospitalizations every year in the U.S. alone. Although there have been modest improvements in treatment, heart failure remains associated with significant mortality and high rates of hospital admission and readmission. We look forward to discussing these results with heart failure experts and potential partners and mapping our clinical development strategy in this exciting new indication.”
The Company has submitted data from this study for presentation at an upcoming medical conference and will provide an update on its plans for MST-188 in heart failure later in 2014.
Details of the Study and Results
The objective of the study was to determine the effect of acute intravenous administration of MST-188 on left ventricular systolic and diastolic cardiac function in a model of chronic heart failure produced by multiple sequential intracoronary microembolizations. A single dose of MST-188 (low or high dose) or placebo was administered over 2 hours. Hemodynamic, ventriculographic, echocardiographic and electrocardiographic measurements were taken at baseline (prior to study drug administration) and at the following time-points after the start of study drug administration: 2 hours (end of administration), 24 hours, 1 week and 2 weeks. Peripheral venous blood samples were obtained at the same time-points. The improvements described above were calculated as the difference between baseline and mean values of each study group at each time-point using a one-way analysis of variance, with p
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).
The Company is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease. In early 2014, the Company plans to initiate a phase 2, clinical proof of concept study in acute limb ischemia that will evaluate whether MST-188 improves the effectiveness of existing thrombolytic agents. The Company also is evaluating development options in heart failure. More information can be found on the Company’s web site at www.masttherapeutics.com. (Twitter: @MastThera)
SOURCE: Mast Therapeutics
Post Views: 232
